Stockscreener 앱 받기
141.32
5.94%
-8.92
Belite Bio Inc Adr 주식(BLTE)의 최신 뉴스
Belite Bio (NASDAQ:BLTE) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Belite Bio (NASDAQ:BLTE) Reaches New 52-Week HighShould You Buy? - MarketBeat
Belite Bio stock hits all-time high at 160.74 USD - Investing.com
Belite Bio stock hits all-time high at 160.74 USD By Investing.com - Investing.com UK
Price-Driven Insight from (BLTE) for Rule-Based Strategy - news.stocktradersdaily.com
Belite Bio (NASDAQ:BLTE) Stock Price Down 5.9%Should You Sell? - MarketBeat
Belite Bio Shares Surge After Landmark Phase 3 Success in Stargardt Disease - MSN
Belite Bio (NASDAQ:BLTE) Sees Strong Trading VolumeShould You Buy? - MarketBeat
Belite Bio (NASDAQ:BLTE) Rating Increased to Outperform at Mizuho - MarketBeat
FY2025 EPS Estimates for Belite Bio Lowered by HC Wainwright - MarketBeat
Belite Bio (NASDAQ:BLTE) Raised to “Outperform” at Mizuho - Defense World
Belite Bio prices 2.27M ADSs at $154.00 to raise $350M in public offering - MSN
Belite Bio (NASDAQ:BLTE) Shares Gap UpWhat's Next? - MarketBeat
Belite Bio stock price target raised to $187 from $132 at Benchmark By Investing.com - Investing.com South Africa
Belite Bio stock price target raised to $187 from $132 at Benchmark - Investing.com Nigeria
Is Belite Bio’s Surge Justified by DCF Upside and Price to Book Signals? - Sahm
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Given Average Recommendation of “Hold” by Brokerages - Defense World
Belite Bio Reports Increased Cash Reserves Amid Rising R&D Costs - The Globe and Mail
Belite Bio Prices $350 Million ADS Offering to Boost Drug Development - TipRanks
Does Belite Bio Inc ADR (BLTE) offer a good opportunity for investors? - Setenews
Mizuho upgrades Belite Bio stock to Outperform on positive trial data By Investing.com - Investing.com South Africa
Mizuho upgrades Belite Bio stock to Outperform on positive trial data - Investing.com Australia
Why Belite Bio’s Stock is Making Waves - TipRanks
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Belite Bio prices public offering of ADSs at $154 each - Investing.com
Belite Bio prices public offering of ADSs at $154 each By Investing.com - Investing.com India
Belite Bio (NASDAQ: BLTE) prices $350M ADS offer to back commercialization, pipeline - Stock Titan
Belite Bio Announces Pricing of $350.0 Million Underwritten Public Offering of American Depositary Shares - GlobeNewswire Inc.
A Look at Belite Bio (BLTE) Valuation Following Positive Tinlarebant Phase 3 Trial Results - Sahm
Why Belite Bio Stock Soared on Monday - Finviz
Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares - markets.businessinsider.com
Belite Bio Q3 2025 Earnings Call Transcript - MarketBeat
Belite Bio launches public offering of American Depositary Shares - Investing.com
Belite Bio Announces Public Offering of ADSs to Fund Expansion - TipRanks
Belite Bio stock falls after announcing public offering of ADSs By Investing.com - Investing.com South Africa
Belite Bio stock falls after announcing public offering of ADSs - Investing.com
Belite Bio (NASDAQ: BLTE) begins ADS sale to support pipeline and commercialization - Stock Titan
Belite Bio stock hits all-time high at 154.0 USD By Investing.com - Investing.com Nigeria
Belite Bio stock hits all-time high at 154.0 USD - Investing.com
Belite continues ascent as Stargardt drug hits mark in late-stage trial - BioPharma Dive
Belite Bio stock soars after breakthrough Phase 3 results for Stargardt disease By Investing.com - Investing.com Canada
Belite Bio stock soars after breakthrough Phase 3 results for Stargardt disease - Investing.com Australia
1.08%
0.91%
자본화:
|
볼륨(24시간):